• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Alcon to pay $60M to acquire Kala Pharmaceuticals’ dry eye treatment

May 23, 2022 By Sean Whooley

Kala Pharmaceuticals Alcon EysuvisAlcon (NYSE:ACL) announced today that it agreed to acquire Eysuvis pharmaceutical eye drops from Kala Pharmaceuticals.

Geneva, Switzerland-based Alcon will pay $60 million upfront to Kala for the dry eye treatment. As part of the agreement, the company will also acquire Kala’s Inveltys corticosteroid for twice-per-day treatment of post-operative inflammation and pain following ocular surgery.

The company may also be required to make additional contingent payments upon the achievement of certain commercial milestones, according to a news release. The transaction is expected to close in the third quarter of 2022.

Eysuvis received FDA approval in January 2021 as the first and only corticosteroid indicated for up to two weeks of treatment for the signs and symptoms of dry eye disease. It utilizes the Ampplify proprietary drug delivery technology to enhance the penetration of loteprednol etabonate into targeted tissue on the ocular surface, helping to prevent flares associated with dry eye disease.

The treatment will be added to Alcon’s portfolio to complement the Systane family of eye drops used for the ongoing management of dry eye symptoms. Eyesuvis (loteprednol etabonate suspension — 0.25% eye drops)  will provide eye care professionals with an option for short-term treatment to mitigate dry eye disease.

Alcon said that revenues for Eysuvis and Inveltys totaled $6.3 million and $4.9 million, respectively, in 2021. The company maintains its current 2022 guidance.

“We will be pleased to add Eysuvis to our growing pharmaceutical portfolio,” Alcon President, North America Sergio Duplan said in the release. “Eysuvis is a natural fit for our newly formed ophthalmic eye drop sales force in the United States. With our strong expertise in market access and commercial execution, we are well-positioned to build the market for acute dry eye treatment.”

Filed Under: Business/Financial News, Featured, Optical/Ophthalmic, Pharmaceuticals Tagged With: Alcon, Kala Pharmaceuticals

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS